bluebird bio Inc reports results for the quarter ended September 30 - Earnings Summary

• bluebird bio Inc BLUE.OQ reported a quarterly adjusted loss of 31 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -66 cents. The mean expectation of ten analysts for the quarter was for a loss of 36 cents per share. Wall Street expected results to range from -46 cents to -28 cents per share.

• Revenue fell 14.4% to $10.61 million from a year ago; analysts expected $18.05 million.

• bluebird bio Inc's reported EPS for the quarter was a loss of 31 cents​.

• The company reported a quarterly loss of $60.81 million.

• bluebird bio Inc shares had fallen by 27.6% this quarter and lost 72.7% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 1% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy," 6 "hold" and 2 "sell" or "strong sell."

• The average consensus recommendation for the pharmaceuticals peer group is also "hold"

Wall Street's median 12-month price target for bluebird bio Inc is 2.50

This summary was machine generated from LSEG data November 14 at 08:58 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)